secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001770787-22-000047
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q2 revenue $114.6M (-1% YoY); net loss $64.5M vs $11.1M loss
-------------------------------------------------------------------------

- Revenue $114.6M, down 1% YoY; gross margin 76% vs 96% due to $14.7M prior-year royalty reversal.
- Operating loss $63.1M (vs $10.3M); net loss $64.5M (vs $11.1M); stock-based comp $36.3M.
- FY2022 revenue guidance cut to $500-520M (2-6% growth) from prior expectations.
- Headwinds: China lockdowns, European cold-chain logistics delays, execution issues, unfavorable FX.
- Launched Fixed RNA Profiling Kit for FFPE; shipped Visium CytAssist; hired Jim Wilbur as CCO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078722000047/0001770787-22-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078722000047/txg-20220808.htm
  HTML page:      https://secwatch.observer/filing/0001770787-22-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer